MedTrace Logo

Teriparatide for Fracture Repair in Humans

NCT02091492 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-09-17

No results posted yet for this study

Summary

This study will test the hypothesis that daily subcuaneous administration of 20µg of teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates proximal 2-segment humerus fracture healing and improves the three dimensional structural properties of bone as measured via quantitative bone image analysis and finite element modeling assessed by quantitative computed tomography.

Conditions

  • Osteoporosis, Age-Related
  • Humeral Fractures

Interventions

DRUG

Teriparatide

Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks

DRUG

Placebo

Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Christian Muschitz, M.D. · Medical University Vienna, St. Vincent Hospital Vienna, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02091492 on ClinicalTrials.gov